Pasithea Therapeutics (KTTA) Total Current Liabilities (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Total Current Liabilities of $1.5 million for Q1 2026, down 70.05% sequentially from $5.0 million in Q4 2025, and down 6.61% YoY from $1.6 million in Q1 2025.
Pasithea Therapeutics (KTTA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Total Current Liabilities fell 6.61% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 6.61% YoY) and the FY2025 annual result came in at $5.0 million, up 344.15% from the prior year.
- Total Current Liabilities slipped to $1.5 million in Q1 2026 per KTTA's latest filing, from $5.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.0 million in Q4 2025 and troughed at $433684.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of $1.6 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 389.33% in 2023, then sank 67.69% in 2024.
- Over 5 years, Total Current Liabilities stood at $1.9 million in 2022, then surged by 40.29% to $2.6 million in 2023, then slumped by 57.48% to $1.1 million in 2024, then soared by 344.15% to $5.0 million in 2025, then slumped by 70.05% to $1.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $1.5 million, $5.0 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Pasithea Therapeutics | 16.08 Mn | 16.08 Mn | - | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 660,397.00 |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 2.47 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 2.23 Mn |
| Mar 31, 2023 | 2.12 Mn |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | 1.51 Mn |
| Jun 30, 2022 | 950,112.00 |
| Mar 31, 2022 | 433,684.00 |
| Dec 31, 2021 | 447,280.00 |
| Sep 30, 2021 | 528,096.00 |
| Dec 31, 2020 | 6,603.00 |